THE DEAL, AT A GLANCE
From the announcementClaris Biotherapeutics
01What it doesImage C/O LifeSci Communications Claris Biotherapeutics is setting its sights on a breakthrough in ophthalmology.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Samsara BioCapital, Catalio Capital ManagementFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedClaris Biotherapeutics raised $118M Series B, announced 2026-08-03From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersClaris Biotherapeutics' $118M Series B positions the company as an above-median Healthcare & Life Sciences financing in a sector with active trailing 30-day capital…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Claris Biotherapeutics · Financing Record
Explore source-linked visual explanations for Claris Biotherapeutics. Unsupported claims are withheld while source review continues.
Record 9542 · Recorded date: 2026-08-03
What it does
Claris Bio is dedicated to advancing transformative therapies for sight-threatening conditions where limited or no treatment options exist.
Source: clarisbio.com ↗